Pulmonary hypertension associated with COPD: a phenotype analysis
Our results highlight the broad spectrum of PH in COPD, from PH associated with end-stage COPD (phenotype/group 1), characterised by predominant alveolar wall damage with severe emphysema, to PVP (phenotype/group 3), mainly due to pulmonary vascular changes. Phenotype/group 2 represents an intermediate state combining features of both. In the current debate on how to distinguish PH-COPD phenotypes, it might be of interest to include quantitative thresholds for emphysema in future diagnostic and management algorithms.
Authors
- Mathilde Steger (ORCID: https://orcid.org/0009-0003-4260-2042)
- Matthieu Canuet (ORCID: https://orcid.org/0000-0002-8089-4846)
- Marianne Riou (ORCID: https://orcid.org/0000-0001-6807-8582)
- Ari Chaouat (ORCID: https://orcid.org/0000-0001-6056-202X)
- Aïssam Labani (ORCID: https://orcid.org/0000-0003-4567-8862)
- Irina Enache (ORCID: https://orcid.org/0000-0002-6405-9082)
- Guillaume Martin (ORCID: https://orcid.org/0009-0008-1625-5215)
- Léo Meyer
- David Montani (ORCID: https://orcid.org/0000-0002-9358-6922)
- Romain Kessler (ORCID: https://orcid.org/0000-0002-5798-5715)
- Armelle Schuller
- Jean Schwartz
Institutions
- Inserm (FR)
- Université Paris-Saclay (FR)
- Regenerative NanoMedicine (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Chest Diseases Hospital (KW)
- Bicêtre Hospital (FR)
- Hôpital Civil, Strasbourg (FR)
- Mitochondrie, stress oxydant et protection musculaire (FR)
- Université de Lorraine (FR)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2024-10-31
- DOI
- https://doi.org/10.1183/23120541.00716-2024
- Citations
- 3
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.26